(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

65 API Suppliers, 24 USDMF, 25 CEP/COS, 7 JDMF, 7 EU WC, 15 KDMF, 34 NDC API, 43 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

70 Drugs in Development

70 Drugs in Development

INTERMEDIATES

6 API Suppliers

6 API Suppliers

FINISHED DOSAGE FORMULATIONS

611 FDF Dossiers, 54 FDA Orange Book, 429 Europe, 23 Canada, 13 Australia, 39 South Africa, 53 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 9MG, AEROSOL, FOAM;RECTAL - 2MG/ACTUATION, SPRAY, METERED;NASAL - 0.032MG/SPRAY, SUSPENSION;INHALATION - 0.25MG/2ML, SUSPENSION;INHALATION - 0.5MG/2ML, SUSPENSION;INHALATION - 1MG/2ML, CAPSULE, DELAYED RELEASE;ORAL - 6MG, CAPSULE, DELAYED RELEASE;ORAL - 9MG, CAPSULE, DELAYED RELEASE;ORAL - 3MG, AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH, AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

RELATED EXCIPIENT COMPANIES

1 Evonik, 1 Rochem International Inc, 5 SPI Pharma, 2 Seqens, 9 DKSH, 1 Jai Radhe Sales, 10 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 11 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 23 BASF, 1 Clariant, 14 Corel Pharma Chem, 4 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 10 Gangwal Chemicals, 9 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 18 Roquette, 14 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 The Dow Chemical Company, 2 Valens Pharmachem, 2 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

67 Coating Systems & Additives, 66 Fillers, Diluents & Binders, 41 Controlled & Modified Release, 33 Thickeners and Stabilizers, 30 Direct Compression, 24 Solubilizers, 20 Film Formers & Plasticizers, 20 Granulation, 19 Lubricants & Glidants, 19 Taste Masking, 18 Topical, 16 Parenteral, 15 Co-Processed Excipients, 11 Disintegrants & Superdisintegrants, 9 Emulsifying Agents, 9 Empty Capsules, 6 Rheology Modifiers, 6 Chewable & Orodispersible Aids, 5 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

DIGITAL CONTENT

5 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 127 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 US Medicaid Prescriptions, 232 Finished Drug Prices, 37 Annual Reports

MARKET PLACE

17 APIs, 17 FDF Dossiers, 1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

53 US Patents, 5 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 USP, 13 Others

ANALYTICAL

3 BioAnalytical Methods

3 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20929 / DOSAGE - SUSPENSION;INHALATION - 0.5MG/2ML

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
BUDESONIDE(UNII: Q3OKS62Q6X) (BUDESONIDE - UNII:Q3OKS62Q6X)	BUDESONIDE	0.5mg in 2

Inactive Ingredients

Ingredient Name	Cardinal Health	The Ritedose Corporation	A-S Medication Solutions	Actavis Pharma, Inc.	American Health Packaging	Amneal Pharmaceuticals of New York LLC	Catalent Pharma Solutions, LLC	Cipla USA Inc.	Exelan Pharmaceuticals, Inc.	NorthStar RxLLC	Preferred Pharmaceuticals Inc.	Preferred Pharmaceuticals, Inc.	Apotex Corp.
ANHYDROUS CITRIC ACID(XF417D3PSL)
CITRIC ACID MONOHYDRATE(2968PHW8QP)
EDETATE DISODIUM(7FLD91C86K)
POLYSORBATE 80(6OZP39ZG8H)
SODIUM CHLORIDE (451W47IQ8X)
SODIUM CHLORIDE(451W47IQ8X)
SODIUM CITRATE(1Q73Q2JULR)
SODIUM CITRATE, UNSPECIFIED FORM(1Q73Q2JULR)
trisodium citrate dihydrate(B22547B95K)
WATER(059QF0KO0R)

Drug Product Composition: (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione